**6. Conclusions**

New therapeutic options emerge as our understanding of preeclampsia improves. Enhancing NO pathway, by overcoming eNOS block and neutralizing raised ADMA values and by homocysteine reduction, may be a perspective goal in the treatment and prevention of PE.

Still new, prospective clinical trials are needed to safely develop e ffective managemen<sup>t</sup> strategies with the use of pharmacological modulators of the NO system, which seem to hold promise for the treatment of preeclampsia.

**Funding:** This research received no external funding.

**Conflicts of Interest:** The authors declare no conflict of interest.
